LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)

• Status: Completed
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to evaluate efficacy, arterial stiffness measured by Pulse Wave Velocity (PWV) of Losartan potassium group compared to Carvedilol group after 24 weeks of treatment in patients with the essential hypertension.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Carvedilol; Hydrochlorothiazide; Losartan

Criteria

Inclusion Criteria:

• Male or Female adults, 18 years or over

• Essential Hypertension with mean SBP (systolic blood pressure) ≥ 140 mm Hg or mean DBP (diastolic blood pressure) ≥ 90 mm Hg* when blood pressure is measured at Visit 1(week -2) and at Visit 2(week 0).

If diabetes patients, mean SBP ≥ 130 mm Hg or mean DBP ≥ 80 mm Hg (Mean of blood pressure values measured consecutively at least 2 minutes apart)

• Patient who is willing to, and is able to sign the informed consent form

Exclusion Criteria:

• Patient Is Pregnant Or Breastfeeding, Or Expecting To Conceive Within The Projected Duration Of The Study

• Patient Has Known Or Suspected Secondary Hypertension Of Any Etiology

• Patient has history of malignant hypertension

• Patient has history of cerebrovascular accident (cerebral infarction) or myocardiac infarction within the last 6 months

• Patient takes antihypertensive drugs